Moreover, the role of KDM1A in schizophrenia is the rationale for EVOLUTION, an adaptive double‐blind placebo‐controlled phase IIb trial in schizophrenia,48 with multiple end points including improvement in negative symptoms and in cognitive impairment associated with schizophrenia. This evidence concerns the gene KDM1A and schizophrenia.